KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Accuray (ARAY) Gains from Sales and Divestitures (2011 - 2025)

Accuray posted quarterly Gains from Sales and Divestitures of $2752.0 for Q2 2025, down 99.88% year-on-year from $2.4 million in Q2 2024, and down 99.88% on a QoQ basis from $2.4 million in Q2 2024.

Accuray (ARAY) has 10 years of Gains from Sales and Divestitures data on file, last reported at $2752.0 in Q2 2025.

  • For the quarter ending Q2 2025, Gains from Sales and Divestitures fell 99.88% year-over-year to $2752.0; the trailing twelve-month figure through Jun 2025 stood at $2752.0 (down 99.88% YoY), and the FY2025 full-year result was $2752.0, down 99.88% from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 stood at $2752.0, down from $2.4 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.4 million in Q2 2024 and bottomed at $2752.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Accuray 47,295.88 -38.49 Mn 25.29 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 2,752.00
Jun 30, 2025 2,752.00
Jun 30, 2024 2.38 Mn
Jun 30, 2024 2.38 Mn
Jun 30, 2019 10,000.00
Jun 30, 2019 10,000.00
Jun 30, 2017 176,000.00
Jun 30, 2017 176,000.00
Jun 30, 2016 20,000.00
Jun 30, 2016 20,000.00
Jun 30, 2015 0.50
Jun 30, 2015 0.50
Jun 30, 2014 888,000.00
Jun 30, 2014 888,000.00
Jun 30, 2013 18,000.00
Jun 30, 2013 18,000.00
Jun 30, 2012 302,000.00
Jun 30, 2012 302,000.00
Jun 30, 2011 202,000.00
Jun 30, 2011 202,000.00